Amyloid-β metabolism in Niemann-Pick C disease models and patients

Metabolic Brain Disease

Volumn 27, Issue 4, 2012, Pages 573-585

  Mattsson, Niklas ^a,e   Olsson, Maria ^a   Gustavsson, Mikael K ^a   Kosicek, Marko ^b   Malnar, Martina ^b   Månsson, Jan Eric ^a   Blomqvist, Maria ^a   Gobom, Johan ^a   Andreasson, Ulf ^a   Brinkmalm, Gunnar ^a   Vite, Charles ^c   Hecimovic, Silva ^b   Hastings, Caroline ^d   Blennow, Kaj ^a   Zetterberg, Henrik ^a   Portelius, Erik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CHILDREN S HOSPITAL OAKLAND   (United States)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Amyloid precursor protein; Amyloid ; Biomarker; Cerebrospinal fluid; Niemann Pick type C

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 3BETA (2 DIETHYLAMINOETHOXY)ANDROST 5 EN 17 ONE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-15]; AMYLOID BETA PROTEIN[1-17]; AMYLOID BETA PROTEIN[1-18]; AMYLOID BETA PROTEIN[1-19]; AMYLOID BETA PROTEIN[1-20]; AMYLOID BETA PROTEIN[1-33]; AMYLOID BETA PROTEIN[1-39]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[5-38]; AMYLOID BETA PROTEIN[5-40]; AMYLOID PRECURSOR PROTEIN; MIGLUSTAT; TAU PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID; CHILD; CONTROLLED STUDY; CULTURE MEDIUM; EXPERIMENTAL CAT; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOPRECIPITATION; LOW DRUG DOSE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NIEMANN PICK DISEASE; NONHUMAN; PHENOTYPE; PRESCHOOL CHILD; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; TANDEM MASS SPECTROMETRY;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BETA-CYCLODEXTRINS; CARRIER PROTEINS; CATS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; IMMUNOPRECIPITATION; INFANT; MALE; MEMBRANE GLYCOPROTEINS; MUTATION, MISSENSE; NIEMANN-PICK DISEASE, TYPE C; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TAU PROTEINS;

EID: 84871406157     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-012-9332-8     Document Type: Article

References (59)

1. Auer IA, Schmidt ML, Lee VM, Curry B, Suzuki K, Shin RW, Pentchev PG, Carstea ED, Trojanowski JQ (1995) Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease. Acta Neuropathol 90(6):547-551
2. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38(11 Pt 1):3751-3757
3. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6(3):131-144
4. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E, for the AABI (2012) Effect of immunotherapy with Bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69(8):1002-1010
5. Bodovitz S, KleinWL (1996) Cholesterolmodulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 271(8):4436-4440
6. Boland B, Smith DA, Mooney D, Jung SS, Walsh DM, Platt FM (2010) Macroautophagy is not directly involved in the metabolism of amyloid precursor protein. J Biol Chem 285(48):37415-37426
7. Borbon IA, Erickson RP (2011) Interactions of Npc1 and amyloid accumulation/deposition in the APP/PS1 mouse model of Alzheimer's. J Appl Genet 52(2):213-218
8. Brinkmalm G, Portelius E, Ohrfelt A, Mattsson N, Persson R, Gustavsson MK, Vite CH, Gobom J,Mansson JE, Nilsson J, Halim A, Larson G, Ruetschi U, Zetterberg H, Blennow K, Brinkmalm A (2012) An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid. J Mass Spectrom 47(5):591-603
9. Burns M, Gaynor K, Olm V, Mercken M, LaFrancois J, Wang L, Mathews PM, Noble W, Matsuoka Y, Duff K (2003) Presenilin redistribution associated with aberrant cholesterol transport enhances beta-Amyloid production in vivo. J Neurosci 23(13):5645-5649
10. Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM (2008) Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 58(1):42-51
11. Crestini A, Napolitano M, Piscopo P, Confaloni A, Bravo E (2006) Changes in cholesterol metabolism are associated with PS1 and PS2 gene regulation in SK-N-BE. J Mol Neurosci 30(3):311-322
12. Davis W Jr (2008) The cholesterol transport inhibitor U18666a regulates amyloid precursor protein metabolism and trafficking in N2aAPP "Swedish" cells. Curr Alzheimer Res 5(5):448-456
13. Erickson RP, Larson-Thome K,Weberg L, Szybinska A, Mossakowska M, Styczynska M, Barcikowska M, Kuznicki J (2008) Variation in NPC1, the gene encoding Niemann-Pick C1, a protein involved in intracellular cholesterol transport, is associated with Alzheimer disease and/or aging in the Polish population. Neurosci Lett 447 (2-3):153-157
14. Grimm MO, Grimm HS, Hartmann T (2007) Amyloid beta as a regulator of lipid homeostasis. Trends Mol Med 13(8):337-344
15. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E,Wallin A, Minthon L, Blennow K (2010) Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31(3):357-367
16. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256(5054):184-185
17. Hecimovic S, Wang J, Dolios G, Martinez M, Wang R, Goate AM (2004) Mutations in APP have independent effects on Abeta and CTFgamma generation. Neurobiol Dis 17(2):205-218
18. Holmes O, Paturi S, Ye W, Wolfe MS, Selkoe DJ (2012) Effects of membrane lipids on the activity and processivity of purified gamma-secretase. Biochemistry 51(17):3565-3575
19. Hook V, Toneff T, Bogyo M, Greenbaum D, Medzihradszky KF, Neveu J, Lane W, Hook G, Reisine T (2005) Inhibition of cathepsin B reduces beta-Amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease. Biol Chem 386(9):931-940
20. Jin LW, Shie FS, Maezawa I, Vincent I, Bird T (2004) Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J Pathol 164 (3):975-985
21. Kagedal K, Kim WS, Appelqvist H, Chan S, Cheng D, Agholme L, Barnham K, McCann H, Halliday G, Garner B (2010) Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. Biochim Biophys Acta 1801(8):831-838
22. Kodam A, Maulik M, Peake K, Amritraj A, Vetrivel KS, Thinakaran G, Vance JE, Kar S (2010) Altered levels and distribution of amyloid precursor protein and its processing enzymes in Niemann-Pick type C1-deficient mouse brains. Glia 58(11):1267-1281
23. Koh CH, Whiteman M, Li QX, Halliwell B, Jenner AM, Wong BS, Laughton KM, Wenk M, Masters CL, Beart PM, Bernard O, Cheung NS (2006) Chronic exposure to U18666A is associated with oxidative stress in cultured murine cortical neurons. J Neurochem 98(4):1278-1289
24. Kosicek M, Malnar M, Goate A, Hecimovic S (2010) Cholesterol accumulation in Niemann Pick type C (NPC) model cells causes a shift in APP localization to lipid rafts. Biochem Biophys Res Commun 393(3):404-409
25. Lange Y, Ye J, Rigney M, Steck T (2000) Cholesterol movement in Niemann-Pick type C cells and in cells treated with amphiphiles. J Biol Chem 275(23):17468-17475
26. Malnar M, Kosicek M, Mitterreiter S, Omerbasic D, Lichtenthaler SF, Goate A, Hecimovic S (2010) Niemann-Pick type C cells show cholesterol dependent decrease of APP expression at the cell surface and its increased processing through the beta-secretase pathway. Biochim Biophys Acta 1802(7-8):682-691
27. Mattsson N, Zetterberg H, Bianconi S, Yanjanin NM, Fu R, Mansson JE, Porter FD, Blennow K (2011) Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a crosssectional study. Neurology 76(4):366-372
28. Mattsson N, Zetterberg H, Bianconi S, Yanjanin NM, Fu R, Mansson JE, Porter FD, Blennow K (2012) Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in Niemann-Pick type C. JIMD Reports 3:45-52. doi:10.1007/8904-2011-47
29. Mattsson N, Portelius E, Rolstad S, Gustavsson M, Andreasson U, Stridsberg M, Wallin A, Blennow K, Zetterberg H (2012a) Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. J Alzheimers Dis 30(4):767-778
30. Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, Olsson M, Brinkmalm G, Lundkvist J, Jacobson LH, Perrot L, Neumann U, Borghys H, Mercken M, Dhuyvetter D, Jeppsson F, Blennow K, Portelius E (2012b) BACE1 Inhibition induces a specific cerebrospinal fluid beta-Amyloid pattern that identifies drug effects in the central nervous system. PLoS One 7(2):e31084
31. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-Terminus of beta-Amyloid. Nat Genet 1(5):345-347
32. Nixon RA, Yang DS, Lee JH (2008) Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy 4(5):590-599
33. Olson L, Humpel C (2010) Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment. Exp Gerontol 45(1):41-46
34. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K (2005) Simultaneous measurement of beta-Amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51(2):336-345
35. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE (2007) Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 6(9):765-772
36. Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F, on behalf of the NPCGWG (2012) Recommendations for the diagnosis and management of Niemann-Pick disease type C: An update. Mol Genet Metab 106(3):330-344
37. Peake KB, Vance JE (2012) Normalization of cholesterol homeostasis by 2-hydroxypropyl-beta-cyclodextrin in neurons and glia from Niemann-Pick C1-deficient mice. J Biol Chem 287(12):9290-9298
38. Pineda M, Wraith JE, Mengel E, Sedel F, Hwu WL, Rohrbach M, Bembi B, Walterfang M, Korenke GC, Marquardt T, Luzy C, Giorgino R, Patterson MC (2009) Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study. Mol Genet Metab 98(3):243-249
39. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K (2006) Determination of beta-Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass Spectrometry. J Proteome Res 5(4):1010-1016
40. Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, Blennow K, Westman-Brinkmalm A (2007) Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed bymass spectrometry. J Proteome Res 6(11):4433-4439
41. Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, Borghys H, Blennow K (2010) Acute effect on the Abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis 21(3):1005-1012
42. Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H (2011a) Novel abeta isoforms in Alzheimer's disease -Their role in diagnosis and treatment. Curr Pharm Des 17 (25):2594-2602
43. Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, Westman-Brinkmalm A, Zetterberg H, Simon AJ, Blennow K (2011b) A novel pathway for amyloid precursor protein processing. Neurobiol Aging 32(6):1090-1098
44. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7(4):321-331
45. Roff CF, Goldin E, Comly ME, Cooney A, Brown A, Vanier MT, Miller SP, Brady RO, Pentchev PG (1991) Type C Niemann-Pick disease: use of hydrophobic amines to study defective cholesterol transport. Dev Neurosci 13(4-5):315-319
46. Rosen C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, Blennow K, Zetterberg H (2012) Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimer's disease. Neuromolecular Med 14(1):65-73
47. Rosenbaum AI, Maxfield FR (2011) Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches. J Neurochem 116(5):789-795
48. Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R, Hartmann T (2002) Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci 22(5):1679-1689
49. Saito Y, Suzuki K, Nanba E, Yamamoto T, Ohno K,Murayama S (2002) Niemann-Pick type C disease: accelerated neurofibrillary tangle formation and amyloid beta deposition associated with apolipoprotein E epsilon 4 homozygosity. Ann Neurol 52(3):351-355
50. Selkoe DJ (1991) The molecular pathology of Alzheimer's disease. Neuron 6(4):487-498
51. Sidera C, Parsons R, Austen B (2005) The regulation of beta-secretase by cholesterol and statins in Alzheimer's disease. J Neurol Sci 229-230:269-273
52. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K (1998) Cholesterol depletion inhibits the generation of betaamyloid in hippocampal neurons. Proc Natl Acad Sci USA 95 (11):6460-6464
53. Somers KL, Royals MA, Carstea ED, Rafi MA, Wenger DA, Thrall MA (2003) Mutation analysis of feline Niemann-Pick C1 disease. Mol Genet Metab 79(2):99-103
54. Stachel SJ, Coburn CA, Steele TG, Jones KG, Loutzenhiser EF, Gregro AR, Rajapakse HA, LaiMT, CrouthamelMC, XuM, Tugusheva K, Lineberger JE, Pietrak BL, Espeseth AS, Shi XP, Chen-Dodson E, Holloway MK, Munshi S, Simon AJ, Kuo L, Vacca JP (2004) Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). JMed Chem47(26):6447-6450
55. Swardfager W, Lanctot K, Rothenburg L,Wong A, Cappell J, Herrmann N (2010) A meta-Analysis of cytokines in Alzheimer's disease. Biol Psychiatry 68(10):930-941
56. Takeda K, Araki W, Akiyama H, Tabira T (2004) Amino-Truncated amyloid beta-peptide (Abeta5-40/42) produced from caspasecleaved amyloid precursor protein is deposited in Alzheimer's disease brain. FASEB J 18(14):1755-1757
57. Vite CH, Ding W, Bryan C, O'Donnell P, Cullen K, Aleman D, Haskins ME, Van Winkle T (2008) Clinical, electrophysiological, and serum biochemical measures of progressive neurological and hepatic dysfunction in feline Niemann-Pick type C disease. Pediatr Res 64(5):544-549
58. Ward S, O'Donnell P, Fernandez S, Vite CH (2010) 2-hydroxypropylbeta- cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease. Pediatr Res 68 (1):52-56
59. Yamazaki T, Chang TY, Haass C, Ihara Y (2001) Accumulation and aggregation of amyloid beta-protein in late endosomes of Niemann-pick type C cells. J Biol Chem 276(6):4454-4460